Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03288493 · OUTCOME

Phase 2: Assess the Safety of P-BCMA-101

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) · Source last updated 2024-03-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Baseline through 24 months

What was measured

Incidence and severity of treatment-emergent adverse events

Groups in this outcome

Phase 2: P-BCMA-101 CAR-T Cells

CAR-T cells administered via intravenous infusion as a total dose

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase 2: P-BCMA-101 CAR-T Cells3

Reported measurements

Source class 1

TEAE Related to P-BCMA-101

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Phase 2: P-BCMA-101 CAR-T Cells2Not reportedNot reportedNot reportedNot reported

TEAE Not Related to P-BCMA-101

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Phase 2: P-BCMA-101 CAR-T Cells1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        2
      title
      TEAE Related to P-BCMA-101
    2. measurements
      1. group Id
        OG000
        value
        1
      title
      TEAE Not Related to P-BCMA-101
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    units
    Participants
description
Incidence and severity of treatment-emergent adverse events
groups
  1. description
    CAR-T cells administered via intravenous infusion as a total dose
    id
    OG000
    title
    Phase 2: P-BCMA-101 CAR-T Cells
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Baseline through 24 months
title
Phase 2: Assess the Safety of P-BCMA-101
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice